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ABSTRACT
Objective:  To report the long-term (30-month) effect of the switch from insulin to sulfonylurea in a 
patient carrying the p.G53D (c.158G>A) mutation in KCNJ11 gene. Subject and method: A 29-year-
-old male patient was diagnosed with diabetes in the third month of life and after identification of 
a heterozygous p.G53D mutation in the KCNJ11 gene, the therapy was switched from insulin to 
sulfonylurea. Results: Long-term follow-up (30 months) showed that good metabolic control was 
maintained (HbA1c: 6.6%) and the glibenclamide dose could be reduced. Conclusion: Long-term 
therapy with sulfonylureas in patients with neonatal diabetes due to mutation in the KCNJ11 gene 
is safe and promotes sustained improvement of glycemic control. Arq Bras Endocrinol Metab. 2010;54(8):682-4 
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RESUMO
Objetivo:  Reportar o efeito a longo prazo (30 meses) da substituição de insulina por sulfonilureia 
em um paciente com a mutação p.G53D (c.158G>A) no gene KCNJ11. Sujeito e método: Pacien-
te do sexo masculino, atualmente com 29 anos de idade, foi diagnosticado com diabetes melito 
no terceiro mês de vida e, após identificação da mutação p.G53D (c.158G>A) em heterozigose 
no gene KCNJ11, a terapia foi substituída de insulina para sulfonilureia. Resultados: Seguimento 
a longo prazo (30 meses) mostrou que o bom controle metabólico foi mantido (HbA1c: 6,6%) 
e a dose de glibenclamida pode ser reduzida. Conclusão: A terapia com sulfonilureia a longo 
prazo em pacientes com diabetes neonatal decorrente de mutações no gene KCNJ11 é segura 
e promove uma melhora persistente no controle metabólico. Arq Bras Endocrinol Metab. 2010;54(8):682-4
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InTRODUCTIOn
Neonatal diabetes mellitus is a rare condition charac-terized by hyperglycemia within the first months of 
life, which may either be permanent or transient. Activat-
ing mutations in the genes KCNJ11 and ABCC8, which 
encode the two subunits Kir6.2 and SUR1 of the pan-
creatic ATP-sensitive potassium channel, are the most 
frequent cause of permanent neonatal diabetes (1-3). 
Approximately 30% of individuals with activating muta-
tions in KCNJ11 have neurologic features in addition to 
neonatal diabetes (4). The main neurologic findings are 
developmental delay, muscle weakness and epilepsy and 
this has been proposed to be part of a syndrome referred 
as DEND (developmental delay, epilepsy and neonatal 
diabetes) syndrome (5). A less severe form without epi-
lepsy is called intermediate DEND syndrome. 
Successful switch from insulin to sulfonylurea (SU) ther-
apy has been reported in the majority of the patients with 
KCNJ11 mutations (6-8); however, there are few reports 
on the long-term efficacy and safety of this change (9-12).
Here we report the long-term (30-month) effect of 
the switch from insulin to sulfonylurea in a patient car-
rying the p.G53D mutation in the KCNJ11 gene.
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PATIEnT PRESEnTATIOn
The patient, who is currently 29 years of age, was di-
agnosed with diabetes in the third month of life during 
a ketoacidosis episode. Insulin treatment was initiated 
at that time and even on intensive insulin therapy, his 
glucose control was erratic with marked hyperglycemia. 
His growth curve was consistently along the 10th per-
centile for height. During follow-up a delay in motor 
milestones was observed: the proband started walking 
autonomously only at 28 months. No muscle weakness 
or lower limb hypotonia was present. Crisis of general-
ized seizures started at age 5 during episodes of hy-
poglycemia, mainly in nocturnal period. His EEG was 
normal. He also showed severe learning difficulties and 
very poor attention and despite receiving special educa-
tion little improvement was achieved.
 At the age of 26 years, informed consent for ge-
netic analysis was obtained from the proband’s parents. 
A blood sample was obtained and genomic DNA was 
extracted from peripheral blood leukocytes using a 
commercial kit (Puregene DNA Isolation Kit, Gentra 
System, Minneapolis, MN, USA). The single exon of 
KCNJ11 was amplified by PCR in three overlapping 
fragments. The PCR products were directly sequenced 
with the use of Big Dye Terminator Cycle Sequenc-
ing Reaction Kit version 3.1 and analyzed on an ABI 
Prism 3100 Genetic Analyzer (Applied Biosystems, 
CA, USA). The proband was found to have a hetero-
zygous change of guanine to adenine on nucleotide 
158, which resulted in glycine to aspartic acid substi-
tution at codon 53 (p.G53D, c.158G>A mutation). 
Both parents were negative for this mutation. On the 
basis of the genotype and clinical features consisting 
of neonatal diabetes with developmental delay but not 
epilepsy, the patient was given a diagnosis of intermedi-
ate DEND syndrome. Following the identification of 
the mutation the patient was transferred from insulin 
to glibenclamide. The initial response to SU therapy 
was previously reported (13). After 4 weeks the patient 
was independent of insulin and using 0.8 mg/kg/day 
of glibenclamide divided into three doses. During the 
following 3 months, as the patient experienced mild 
hypoglycemic episodes, the glibenclamide dose was 
reduced to 0.68 mg/kg/day. A 72-hour continuous 
glucose monitoring system (CGMS, Medtronic Min-
imed, Sylmar CA, USA) showed mean glucose of 108 
mg/dL with 71% of glycemic values between 80 and 
200 mg/dL and 1% values above 200 mg/dL (Fig-
ure 1A). HbA1c levels reduced from 8.2% to 7.6% 3 
months after the transfer. A weight loss of 3.8 kg was 
observed in the first 8 weeks of SU therapy with sub-
sequent weight stabilization. Currently, 30 months af-
ter the introduction of SU, good metabolic control is 
maintained (HbA1c: 6.6%) and the glibenclamide dose 
was reduced to 0.55 mg/kg/day. During the course 
of SU therapy no severe hypoglycemic episodes were 
reported. Another 72-hour continuous glucose moni-
toring was performed and showed mean glucose of 107 
mg/dL with 80% of glycemic values between 80 and 
200 mg/dL and none above 200 mg/dL (Figura 1B). 
Incipient diabetic nephropathy was diagnosed 9 years 
ago and therapy with ACE-inhibitors was initiated at 
that time. Fourteen months after the introducing SU, 
microalbuminuria in nocturnal collection of urine de-
creased from 77 ug/min to 32 ug/min and remained 
stable through the follow-up period.
The investigation was approved by the Ethics Com-
mitte of Escola Paulista de Medicina, Universidade 
Federal de São Paulo.
Figure 1. Glucose levels captured by the 72-h continuous glucose monitoring system 3 months (A) and 30 months (B) after switching from insulin to 
glibenclamide therapy. Each line represents a 24-h period.
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DISCUSSIOn
Activating mutations in the genes encoding the ATP-
sensitive potassium channel causes failure of this chan-
nel to close in response to increased intracellular ATP, 
thus inhibiting insulin secretion. However, sulfonyl-
ureas bind to the SUR1 subunit and close the ATP-
sensitive channel by an ATP-independent mechanism 
resulting in insulin release even in cells with activated 
mutations in KCNJ11 (14).
We describe herein a 30-month experience of sul-
fonylurea treatment in an adult patient with interme-
diate DEND syndrome due to p.G53D mutation in 
KCNJ11. Following the transfer from insulin to SU 
we observed marked improvement in glycemic control 
that was maintained over the follow-up period, despite 
decreasing SU doses. No side effects were reported. 
The successful transfer to SU is consistent with the pre-
vious report of a patient with permanent neonatal dia-
betes carrying the same mutation (15). To examine the 
consequences of this mutation, Koster and cols. (15), 
coexpressed a mutant Kir6.2 subunit containing the 
p.G53D mutation with the wild-type SUR1 subunit. 
Channel activity in intact cells was screened by 86Rb+-
efflux and ATP sensitivity was measured directly in ex-
cised membrane patches (15). The authors have dem-
onstrated an increased channel activity and reduced 
ATP sensitivity by approximately 20 fold in homomeric 
channels.
There are few reports of chronic diabetes complica-
tions in patients with neonatal diabetes and the role of 
SU treatment in their evolution. Klupa and cols. (10) re-
ported progression of a pre-existing diabetic retinopathy 
in a patient whose treatment was transferred from insulin 
to SU (10). Despite no causal relationship between the 
retinal changes and SU treatment could be proven, the 
authors recommend special ophthalmological attention 
in subjects with pre-existing advanced diabetic retinopa-
thy. Our patient had no diabetic retinopathy when sul-
fonylurea was initiated and no evidence of this complica-
tion was found during the follow-up period. Reduction 
in microalbuminuria was observed during SU therapy 
possibly related to the improvement of metabolic con-
trol. Klupa and cols. (12) also observed some regression 
in the albumin/creatinine ratio in one patient.
In summary, this case illustrates that switching from 
insulin to sulfonylurea is safe and promotes sustained im-
provement of glycemic control on long-term follow-up. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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